Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Company Overview - Leap Therapeutics, Inc. is a biotechnology company focused on developing targeted and immuno-oncology therapeutics [3] - The company's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf1 (DKK1) protein, being developed for esophagogastric, gynecologic, and colorectal cancers [3] Study Update - Enrollment of 188 patients has been completed in Part B of the DeFianCe study, which evaluates DKN-01 in combination with standard care bevacizumab and chemotherapy for advanced colorectal cancer (CRC) [1][2] - The DeFianCe study is a Phase 2, open-label, global study, with the primary endpoint being progression-free survival (PFS) [2] - Part B of the study expanded from 130 to 188 patients, and an additional primary endpoint will measure PFS in patients with left-sided CRC [2] Clinical Data and Expectations - Initial data from Part B, including results for the subpopulation of patients with left-sided CRC, is expected to be shared in mid-2025 [2] - Encouraging data from Part A of the study showed clinically meaningful response rates and durable tumor reductions, along with a favorable safety profile in advanced CRC patients [2]